Sumaiya Sharmeen to speak at the ACI’s Summit on Biosimilars & Innovator Biologics

Morrison Foerster partner Sumaiya Sharmeen will be a featured speaker at the ACI's 17th Summit on Biosimilars & Innovator Biologics, taking place June 2–3, 2026 at 3 Times Square in New York.

The summit brings together in-house counsel, regulators, and litigators to benchmark on the evolution of the global biosimilar and innovator markets, IP disputes, regulatory hurdles, and market access strategies.

Sumaiya's panel, "Uncertainty at the intersection of artificial intelligence and IP strategies: has AI altered product development and litigation planning?" will explore how AI's rapid integration into biologics research, regulatory strategy, patent analytics, and competitive intelligence is creating a new layer of legal and strategic uncertainty for biosimilar developers. Panelists will examine strategies and challenges associated with harnessing AI's potential, and review best practices for mitigating operational and litigation risks inherent in emerging AI technology.